Accessibility Menu
Galmed Pharmaceuticals Stock Quote

Galmed Pharmaceuticals (NASDAQ: GLMD)

$1.43
(0.7%)
+0.01
Price as of October 21, 2025, 3:59 p.m. ET

KEY DATA POINTS

Current Price
$1.43
Daily Change
(0.7%) +$0.01
Day's Range
$1.38 - $1.44
Previous Close
$1.43
Open
$1.41
Beta
0.82
Volume
33,631
Average Volume
166,655
Market Cap
7.8M
Market Cap / Employee
$1.42M
52wk Range
$1.15 - $4.81
Revenue
-
Gross Margin
-
Dividend Yield
N/A
EPS
-$5.49
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Galmed Pharmaceuticals Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
GLMD-69.44%-99.76%-70.13%-100%
S&P+15.06%+95.03%+14.29%+266%

Galmed Pharmaceuticals Company Info

Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$0.00M0.0%
Gross Profit$0.00M100.0%
Market Cap$4.15M151.4%
Market Cap / Employee$0.69M0.0%
Employees6-25.0%
Net Income-$2.50M-123.0%
EBITDA-$2.11M-83.7%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$5.09M160.2%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$0.00M0.0%
Short Term Debt$0.00M0.0%

Ratios

Q2 2025YOY Change
Return On Assets-48.07%-3.9%
Return On Invested Capital-79.80%-3.4%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$1.27M-24.7%
Operating Free Cash Flow-$1.27M-24.7%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book0.310.260.150.2589.97%
Price to Tangible Book Value0.310.260.150.2589.97%
Enterprise Value to EBITDA5.756.1710.516.35-11.25%
Return on Equity-37.3%-49.8%-49.6%-54.0%2.51%
Total Debt$0.00M$0.00M$0.00M$0.00M-

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.